Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Union Budget
Budget 2011-2012 Home
Industry Expectations - Budget 2011-2012
Industry Reactions - Budget 2011-2012
Budget 2010-2011
Budget 2010-2011 Home
Industry Expectations - Budget 2010-2011
Industry Reactions - Budget 2010-2011
Contributor's Corner
Bonanza Portfolio
Hemant K Gupta
Krish Bhatt
S A A R T H I
Trinity Investments
Exchange Information
BSE 2009 Holidays
NSE 2009 Holidays
Investor Guide
Depository & Dematerialisation
Grievance Redressal
Investor Guide
SEBI
Trading of Securities
Transfer of Securities
Your Rights
Budget 2009-2010
Budget 2009-2010 Home
Industry Expectations - Budget 2009-2010
Industry Reactions - Budget 2009-2010
Interim Budget 2009-2010 Home
Industry Expectations - Interim Budget 2009
Budget 2008-2009
Railway Budget 2008-2009
Industry Expectations - Budget 2008
Union Budget 2008-2009
Highlights of Budget 2008-2009
Summary of Budget 2008-2009
Industry Reactions - Budget 2008
IPOs
Current IPOs
Past IPOs
IPO Subscription
Mutual Funds
Gold Exchange Traded Fund
MF Unique Holding
Forthcoming Dividends
ELSS Schemes Comparison
Tax Plans
New Fund Offers
Research
Arbitrages
Equity
Market Whispers
Tax Planning
Home
Equity Linked Savings Scheme
Post Office MIS
9% GOI Senior Citizens Savings Scheme
8% Savings (Taxable) Bonds
Kisan Vikas Patra
National Savings Certificate
Public Provident Fund
Research

| More

BUY Vivimed Labs - Better pharma growth, lower interest cost drive earning - Anand Rathi

Posted On: 2016-08-18 20:05:03

Vivimed Labs - Better pharma growth, lower interest cost drive earnings; Buy with a target price of Rs 133

Vivimed registered a decent Q1 FY17. A 10.7% yoy increase in revenue and a steep drop in interest costs pushed up PAT 15.2% yoy to Rs. 279m. We believe the launches in the US market and the focus on a better product mix in specialty chemicals would lead to greater profitability. We are positive about Vivimed and retain our Buy rating, with a price target of Rs. 133.

Robust earnings. Vivimed's Q1 FY17 10.7% yoy revenue growth to Rs. 3.7bn, beat our estimated Rs. 3.5bn. However, its EBITDA margin declined 205bps to 18.1% (in -line with our estimate) due to the lower gross margin. Though EBITDA was steady yoy, PAT grew 15% yoy to Rs. 279 (our estimate: Rs. 222m), due to a sharp drop in interest on reduction in debt.

Healthy revenue. Revenue growth of 10.7% was primarily driven by 22% yoy growth in its pharma division to Rs. 2.9bn, which now brings in 78% of revenue. The pharma division growth was largely driven by API as formulations were relatively muted. Pharma had a 12.5% EBIT margin. The pharma divsion EBIT margin improved sequentially. Specialty chemical sales continued to decline yoy due to the sale of some part of the business to Clariant. As a result, the specialty chemical division contracted 16% yoy to Rs. 800m. Due to sale of part of the low-margin specialty-chemicals business, Vivimed had a good 19% EBIT margin, up 82bps yoy, 640bps qoq.

luation. The stock trades at attractive valuations of 6.1x FY17e and 4.5x FY18e earnings. We are positive about it because of the better product mix, lower financial leverage and greater operating efficiency. We maintain our Buy rating, with a price target of Rs. 133 based on 8x FY18e EPS. Risks. Delay in regulatory approvals, currency fluctuations.

Shares of VIVIMED LABS LTD. was last trading in BSE at Rs.75.2 as compared to the previous close of Rs. 75.15. The total number of shares traded during the day was 44865 in over 314 trades.

The stock hit an intraday high of Rs. 76.5 and intraday low of 74.75. The net turnover during the day was Rs. 3400293.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com


Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only. www.equitybulls.com, its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. www.equitybulls.com or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.





Other Headlines:

Supreme Industries - Visit Note - Plastic Industry Juggernaut - Nirmal Bang
Crompton Greaves Consumer Electricals - Initiating Coverage - Rechristened For An Electrifying Future - Nirmal Bang
AU Small Finance Bank - IPO Update - Unique Positioning - Nirmal Bang
AU Small Finance Bank Ltd - IPO Note - Angel Broking
Company Visit Note: Maithan Alloys Ltd. (MAL) - NOT RATED - Kotak
Economy/Strategy: GST: Godot has arrived - Kotak
The Pitch Report: Karnataka Bank Ltd - BUY - TP Rs.220 - Kotak
Company Update: Voltas Ltd - ACCUMULATE - TP Rs.500 - Kotak
Technology: Accenture-tightens revenue growth guidance band - Kotak
Metals & Mining (Attractive): India Steel-on a recovery path - Kotak
Nasscom guides for 7-8% growth, lower than 8.6% in c/c of FY2017 - Kotak
Technology: Nasscom guidance - Decelerating growth trend continues - Kotak
Company Visit Note: Huhtamaki PPL Ltd (HPPL) - NOT RATED - Kotak
Company Update: Shipping Corporation of India - BUY - TP Rs.110 - Kotak
IT Industry to grow at 8-9% in FY2018; Nasscom: Angel Broking
Lupin - USFDA update: Angel Broking
Company Visit Note: The Mandhana Retail Ventures Ltd - NOT RATED - Kotak
Banks : Offers protection in adverse conditions - A deeper study into Pradhan Mantri Fasal Bima Yojana - Agriculture Insurance scheme - Kotak
Energy - downstream PSUs: When the tide turns - Kotak
Company Update: Mahindra and Mahindra (M&M) - BUY - TP Rs.1565 - Kotak
Maharashtra government removes cap on taxi / auto licenses: Angel Broking
IPCA Labs - USFDA update: Angel Broking
Company Update: Gujarat State Petronet Ltd (GSPL) - ACCUMULATE - TP Rs.182 - Kotak
Management Meet Update - Zensar Technologies - CSEC Research
Company Update: VRL Logistics Ltd - BUY - TP Rs.375 - Kotak
Strategy: The impossible trinity of farm income - Kotak
Banks : Private banks accelerate gains on CASA : Deeper study into deposit profile of banks for FY2016 - Kotak
Company Update: Blue Star - ACCUMULATE - TP Rs.684 - Kotak
Banking : RBI gets into action - Kotak
Dr Reddy's - EIR for its Miryalaguda API plant: Angel Broking
Eris Lifesciences Limited - IPO Note - Angel Broking
Banks: Maharashtra announces farm loan waiver - Kotak
Company Update: Petronet LNG - ACCUMULATE - TP Rs.462 - Kotak
Company Update: Mirza International - REDUCE - TP Rs.161 - Kotak
Fiem Industries - BUY - TP Rs.1,254 - Kotak
Insurance: ICICI Prudential Life boosts industry growth - Kotak
Tejas Networks - A destination for high speed technology: Angel Broking
Hindalo Industries - Result Update - Strong show becoming a routine, maintain Buy - Centrum
Star Cement - Result Update - Profitability rebounds on better pricing, cost reduction - Centrum
FIEM Industries - Result Update - Negatives priced in, Well poised to gain in the long term - Centrum
Birla Corporation - Strong Q4 FY17; acquisition reporting strong numbers; Buy - Anand Rathi
Escorts Ltd - Ready for next leg - PhillipCapital
Earnings Update - Talwalkars Better Value Fitness (TBVF IN) - Results on expected line - CSEC Research
Result Update: Adani Port and Special Economic Zone (APZ) - BUY - TP Rs.425 - Kotak
Telecom: Two quarters of Jio - assessing the impact - Kotak
Earnings Update - Balkrishna Industries (BIL IN) - Strong volume growth continues - CSEC Research
Earnings Update - Kaveri Seeds Ltd(KSCL IN) - Muted performance - CSEC Research
Earnings Update - TTK Prestige (TTKPT IN) - Results in-line with expectation - CSEC Research
Earnings Update - Berger Paints (BRGR IN) - Results in-line with expectation - CSEC Research
Mayur Uniquoters - Footwear segment dragged performance; Maintain Hold - Awanish Chandra and Vikas Rajpal - Centrum


Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2017